Group 1 - The core viewpoint of the articles highlights the financial performance and market position of Zhendermedical, indicating a decline in net profit despite a slight increase in revenue [1][2] - Zhendermedical's closing stock price is 20.86 yuan, with a rolling PE ratio of 15.31 times, which is significantly lower than the industry average of 49.70 times [1][2] - The company has a total market capitalization of 5.558 billion yuan, ranking 36th in the medical device industry based on PE ratio [1][2] Group 2 - As of the first quarter of 2025, 15 institutions hold shares in Zhendermedical, with a total holding of 154.3014 million shares valued at 3.331 billion yuan [1] - The main business of Zhendermedical includes the research, production, and sales of medical and health products, with key products in basic care, surgical infection control, pressure treatment, and modern wound care [1] - The latest financial report shows that for the first quarter of 2025, the company achieved an operating income of 999.2 million yuan, a year-on-year increase of 2.87%, while net profit was 51.2419 million yuan, a year-on-year decrease of 30.19% [1]

Group 1 - The stock price of Zhendemedical (603301) closed at 20.83 yuan as of June 6, 2025, with no change from the previous week, and the market capitalization is 5.55 billion yuan [1] - The highest intraday price for Zhendemedical was 21.0 yuan on June 4, 2025, while the lowest was 20.7 yuan on June 5, 2025 [1] - Zhendemedical ranks 54th out of 126 in the medical device sector by market capitalization and 2681st out of 5148 in the A-share market [1] Group 2 - Zhendemedical announced an extension of its first employee stock ownership plan by six months, now set to expire on January 2, 2026 [1][3] - The company plans to distribute a cash dividend of 0.65 yuan per share, with the record date on June 10, 2025, and the payment date on June 11, 2025 [2][3] - The total cash dividend to be distributed amounts to approximately 173.11 million yuan (including tax), based on a total share count of 266,321,760 shares [2]

证券代码：603301 证券简称：振德医疗 公告编号：2025-019 振德医疗用品股份有限公司2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.65元 相关日期 | | 股权登记日 2025/6/10 | | | | | --- | --- | --- | --- | --- | | | | 最后交易日 － | | | | | | | 除权（息）日 2025/6/11 | 现金红利发放日 2025/6/11 | | 股份类别 Ａ股 | | | | | 差异化分红送转： 是 一、 通过分配方案的股东大会届次和日期 本次利润分配方案经公司2025 年 5 月 19 日的2024年年度股东大会审议通过。 截至股权登记日下午上海证券交易所收市后，在中国证券登记结算有限责任公司上海分 公司（以下简称"中国结算上海分公司"）登记在册的本公司全体股东（公司回购专用证券账 户中的股份不参与利润分配）。 3. 差异化分红送转方案： （1）本次差异化分红送转方案 ...

国枫律证字[2025]AN062-1号 差异化分红事项的 专项核查意见 北京国枫律师事务所 关于振德医疗用品股份有限公司 GRANDWAY 北京国枫律师事务所 Grandway Law Offices 北京市东城区建国门内大街 26 号新闻大厦 7 层、8 层 邮编: 100005 电话（Tel）: 010-88004488/66090088 传真（Fax）: 010-66090016 北京国枫律师事务所 关于振德医疗用品股份有限公司 差异化分红事项的 专项核查意见 国枫律证字[2025]AN062-1 号 致: 振德医疗用品股份有限公司（公司） 北京国枫律师事务所(以下简称"本所")接受公司的委托,根据《中华人民共和 国公司法》(以下简称"《公司法》")、《中华人民共和国证券法》(以下简称"《证 券法》"）、《上市公司股份回购规则》(以下简称"《回购规则》"、《上海证券交易所 上市公司自律监管指引第７号——回购股份》(以下简称"《监管指引第７号》")等相关 法律、行政法规、规章、规范性文件及《振德医疗用品股份有限公司章程》(以下简称 "《公司章程》"）的规定,就公司 2024年度利润分配所涉及的差异化分红( ...

Summary of Key Points Core Viewpoint - Zhendemedical (603301) has made significant progress in sustainable development and social responsibility, as highlighted in its 2024 ESG report, while also announcing a loan agreement and an extension of its employee stock ownership plan. Group 1: Trading Information - On May 30, 2025, Zhendemedical's stock closed at 20.83 yuan, with a slight increase of 0.34% and a turnover rate of 0.8% [1] - The trading volume was 21,300 shares, with a total transaction amount of 44.2142 million yuan [1] - The fund flow on the same day showed a net outflow of 3.6882 million yuan from main funds, a net inflow of 4.6381 million yuan from speculative funds, and a net outflow of 949,900 yuan from retail investors [1][4] Group 2: Company Announcements - Zhendemedical released its 2024 Sustainable Development Report, emphasizing governance, employee care, green development, and reliable cooperation, with notable advancements in compliance management and climate change response [2] - The company participated in the EcoVadis rating in 2024 and received a silver medal, while also launching a 2030 carbon pathway plan and committing to the Science Based Targets initiative (SBTi) [2] - Zhendemedical's R&D investment for the year reached 135.49 million yuan, resulting in 9 new Class II medical device registrations and 28 invention patents [2] - The company announced a loan agreement with the International Finance Corporation (IFC) for up to 30 million USD, with a repayment period from 2029 to 2033 [2] - The first employee stock ownership plan has been extended by 6 months until January 2, 2026, due to unliquidated shares [3][5]

Group 1 - The core point of the announcement is the extension of the first employee stock ownership plan of the company by 6 months, now set to expire on January 2, 2026 [1][2][3] - The employee stock ownership plan was initially approved in meetings held on May 24, 2021, and June 15, 2021, with details available on the Shanghai Stock Exchange website [1][2] - As of the announcement date, the employee stock ownership plan holds 615,700 shares, representing 0.23% of the company's total share capital [2] Group 2 - The extension of the plan was approved due to the fact that the shares held under the plan had not been fully disposed of, requiring a majority agreement from the plan holders [2][3] - The management committee of the employee stock ownership plan will manage the disposal of shares in compliance with relevant laws and regulations [3] - The company will continue to monitor the implementation of the employee stock ownership plan and fulfill its information disclosure obligations as required by law [3][4]

关于公司第一期员工持股计划延期的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 振德医疗用品股份有限公司（以下简称"公司"）第一期员工持 股计划（以下简称"本员工持股计划"）的存续期将于 2025 年 7 月 2 日届满。2025 年 5 月 30 日，公司召开第三届董事会第二十一次会 议，审议通过了《关于公司第一期员工持股计划延期的议案》，同意 将本员工持股计划存续期延长 6 个月，即延长至 2026 年 1 月 2 日， 现将相关情况公告如下： 一、本员工持股计划的基本情况 公司分别于 2021 年 5 月 24 日、2021 年 6 月 15 日召开第二届董 事会第十七次会议和 2021 年第二次临时股东大会，审议通过了《关 于<公司第一期员工持股计划（草案）>及其摘要的议案》等相关议案， 同意实施公司第一期员工持股计划，具体内容详见公司于 2021 年 5 月 25 日、2021 年 6 月 16 日在上海证券交易所网站（www.sse.com.cn） 披露的公告。 2021 年 7 月 2 日，公司收到中国证券 ...

Core Viewpoint - The company has provided a guarantee of up to USD 30 million for its wholly-owned subsidiary, Singapore New Start, to secure a loan from the International Finance Corporation (IFC) [1][2]. Group 1: Guarantee Overview - The guarantee amount provided by the company and its subsidiaries for Singapore New Start totals USD 30 million, equivalent to RMB [1]. - There is no counter-guarantee provided for this loan [2]. - The cumulative number of overdue external guarantees is zero [1]. Group 2: Internal Decision-Making Process - The company’s board of directors approved the guarantee during meetings held on April 24, 2025, and May 19, 2025, within the limits set by the 2024 annual shareholders' meeting [2][5]. Group 3: Financial Status of the Guaranteed Entity - Singapore New Start has total assets of RMB 83,491.29 million as of March 31, 2025, and total liabilities of RMB 83,293.35 million, resulting in a net asset of RMB 197.94 million [3][4]. - The company reported a revenue of RMB 9,321.49 million and a net profit of RMB 71.46 million for the first quarter of 2025 [4]. Group 4: Necessity and Reasonableness of the Guarantee - The guarantee is deemed necessary for the daily operations and business development of the subsidiary, aligning with the company's overall interests and strategic goals [5]. - The guarantee amount is within the limits approved by the shareholders' meeting, and the company maintains control over the subsidiary's operational activities and credit status [5]. Group 5: Cumulative External Guarantees - As of the announcement date, the cumulative external guarantee amount provided by the company and its subsidiaries is equivalent to 3.82% of the company's net assets [5]. - The company has not provided guarantees for its controlling shareholders or related parties, and there are no overdue guarantees [5].

证券代码：603301 证券简称：振德医疗 公告编号：2025-017 振德医疗用品股份有限公司 关于提供担保的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●被担保人名称：公司全资下属公司新起点（新加坡）私人有限 公司（以下简称"新加坡新起点"） ●本次担保金额：振德医疗用品股份有限公司（以下简称"公司"） 及其全资子公司香港新起点投资有限公司、振德医疗用品(香港)有限 公司（前述三方以下简称"担保人"）为新加坡新起点提供最高额为 3,000 万美元等值人民币的保证担保。 截止本公告日，包括本次担保在内，公司及控股子公司为新加坡 新起点提供的担保余额为 3,000 万美元等值人民币。 ●本次担保是否有反担保：无 ●对外担保逾期的累计数量：无 ●特别风险提示：本次担保对象最近一期资产负债率存在超过 70% 的情形，敬请投资者注意相关风险。 一、本次担保情况概述 （一）本次担保基本情况 近日，公司全资下属公司新加坡新起点与 INTERNATIONAL FINANCE CORPORATION（以下简称" ...

2024 2024 Sustainability Report ZHENDE MEDICAL CO., LTD. 2 3 | About This Report | 5 | | --- | --- | | About Zhende Medical | 8 | | Message from the Chairman: After | | | thirty years of efforts, embark on the path | | | of high-quality development through | | | ESG | 11 | | Performance for Sustainable Devel | | | opment in 2024 | 13 | | 01 | Sustainable Development | 14 | | --- | --- | --- | | | Management | | | | We Care | 14 | | | Management Structure and Responsibilities of | | | | Sustainable Developme ...